Medplus Health Services Limited
MEDPLUS · Hospitals · NSE
₹865
Current Market Price
Fair Value (DCF)
₹995
Margin of Safety
+15.0%
Updated 22h ago
YieldIQ Score
37/100
Piotroski F-Score
6/9
Economic Moat
None
Confidence
31%
ROE
8.6%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.10 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
10.3%
Return on capital employed
EV / EBITDA
18.7×
Enterprise multiple
Debt / EBITDA
1.8×
Leverage vs earnings
Interest Coverage
2.8×
EBIT covers interest
Current Ratio
3.20×
Short-term liquidity
Asset Turnover
1.90×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹865.25
Bear case
₹405.46
MoS -113.4%
Base case
₹995.04
MoS +13.0%
Bull case
₹1,044.79
MoS +17.2%
Ratio Trends
MEDPLUS · last 4 annual periods
ROE
8.6%
ROCE
18.7%
Operating Margin
—
Debt / Equity
0.64×
PE
293.6×
EV / EBITDA
24.2×
Historical Financials
MEDPLUS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹3779 Cr | ₹1253 Cr | ₹1490 Cr | ₹6087 Cr | +17.2% |
| EBITDA | ₹304 Cr | ₹312 Cr | ₹394 Cr | ₹536 Cr | +20.8% |
| EBIT | ₹184 Cr | ₹39.5 Cr | ₹57.1 Cr | — | -32.3% |
| PAT | ₹94.7 Cr | ₹26.6 Cr | ₹33.6 Cr | ₹150 Cr | +16.6% |
| EPS (diluted) | ₹8.52 | ₹2.24 | ₹2.79 | — | -31.1% |
| CFO | ₹170 Cr | ₹90.4 Cr | ₹144 Cr | ₹540 Cr | +47.1% |
| CapEx | — | — | — | ₹-59.5 Cr | — |
| FCF | — | — | — | ₹481 Cr | +0.0% |
| Total Assets | ₹2594 Cr | ₹2797 Cr | ₹3005 Cr | ₹3360 Cr | +9.0% |
| Total Debt | — | ₹0.0 Cr | ₹0.0 Cr | ₹1120 Cr | — |
| Shareholders' Equity | — | ₹1491 Cr | ₹1578 Cr | ₹1740 Cr | +5.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MEDPLUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SANOFICONR SANOFICONR | — | — | Pending | 62.5% | — |
| VIJAYA VIJAYA | — | — | Pending | 17.9% | — |
| CONCORDBIO CONCORDBIO | — | — | Pending | 20.5% | — |
| METROPOLIS METROPOLIS | — | — | Pending | 10.9% | — |
| INDGN INDGN | — | — | Pending | 15.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for MEDPLUS in the last 10 years.
AI Analysis Summary
Medplus Health Services appears undervalued by 15.0%, with a standout strength of zero debt, but a concern is its low YieldIQ score of 37/100.
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MEDPLUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MEDPLUS →
Compare
Head-to-head with peers
Compare MEDPLUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MEDPLUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.